Aqemia is an Ile-de-France-based company founded in 2019 using in silico machine learning methods to discover and develop new drugs. The Aqemia generative artificial intelligence (AI) creates molecular compounds and predicts the molecules' interactions as pharmaceutical compounds within specific patients. Initially, Aqemia was developed at École Normale Supérieure Paris. However, it became a spin-off company in 2019 when it was formally founded by Maximilien Levesque, the current CEO, and Emmanuelle Martiano, the current COO.
École Normale Supérieure Paris is considered a selective and prestigious graduate school located in Paris, France. Maximilien Leveque was a university professor teaching quantum mechanics and theoretical chemistry from 2014 to 2017 before teaching machine learning from 2017 to 2020. During Leveque's career at École Normale Supérieure, he was a research group leader (2014-2020), where he developed the technology for Aqemia.
"With its first financing round, the company is looking to recruit the first members of its team. Specifically, CEO Levesque and COO Emmanuelle Martiano want to hire in silico drug hunters, software developers, and experts in generative artificial intelligence."
Aqemia and Servier announce AI and quantum physics-drive drug discovery collaboration in immuno-oncology
December 16, 2021
- Drug discoveryDrug discovery is the process by which new candidate medications are discovered.
- Artificial intelligenceTopics related to artificial intelligence.
- Quantum computingThe study of computation systems that make use of quantum mechanical phenomena (eg entanglement and superposition). Quantum computers use qubits (rather than binary 0 and 1s) which can be in both states at the same time by being in a superposition of states.
- Pharmaceutical industryDevelops, produces, and markets drugs or pharmaceuticals licensed for use as medications